IVC Treatment Between Primary and Second TURBT May Improve the Prognosis of High-risk NMIBC Patients Receiving BCG Treatment

Overview

Journal Sci Rep

Date 2025 Feb 10

PMID 39930090

Authors

Zhen Li

Zewei Wang

Yang Liu

Lei Yang

Ling Gu

Hailong Li

Wei Wang

Affiliations

Soon will be listed here.

Abstract

To explore whether intravesical chemotherapy (IVC) between primary and second transurethral resection of bladder tumor (TURBT) affects the prognosis of non-muscle invasive bladder cancer (NMIBC) patients receiving Bacillus Calmette-Guérin (BCG) treatment. NMIBC patients who underwent a second TURBT and subsequent BCG treatment between 2012 and 2023 at the Affiliated Hospital of Xuzhou Medical University were retrospectively analyzed. These patients were divided into Group A, which received IVC between TURBT, and Group B, which did not. Recurrence-free survival (RFS) was compared among the different risk subgroups. A total of 292 NMIBC patients were included in this study. In the entire cohort, IVC treatment between the primary and second TURBT was associated with longer RFS (P = 0.009). When stratified by risk groups, in intermediate-risk patients, the difference in RFS between the groups was not statistically significant (P = 0.434). By contrast, for high-risk patients, the treated group exhibited a better prognosis compared to the non-treated group (85.6% vs. 77.6%, P = 0.007). In both univariate and multivariate COX regression analyses, after adjusting for clinical factors such as tumor stage and tumor grade, the IVC between the primary and second TURBT remained an independent prognostic factor for NMIBC patients (HR 0.571, 95% CI [0.380, 0.859], p = 0.007). IVC treatment administered between the primary and second TURBT has been demonstrated to enhance RFS of high-risk NMIBC patients undergoing BCG treatment, whereas it is not applicable to intermediate-risk patients.

References

Tabayoyong W, Kamat A, ODonnell M, McKiernan J, Ray-Zack M, Palou J . Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer. Eur Urol Focus. 2018; 4(4):512-521. PMC: 7810510. DOI: 10.1016/j.euf.2018.08.019. View

Brauers A, Buettner R, Jakse G . Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early?. J Urol. 2001; 165(3):808-10. View

Grabe-Heyne K, Henne C, Mariappan P, Geiges G, Pohlmann J, Pollock R . Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Front Oncol. 2023; 13:1170124. PMC: 10272547. DOI: 10.3389/fonc.2023.1170124. View

Lee K, Jeong S, Yoo S, Ku J . Evaluating the efficacy of secondary transurethral resection of the bladder for high-grade Ta tumors. Investig Clin Urol. 2022; 63(1):14-20. PMC: 8756150. DOI: 10.4111/icu.20210314. View

Bree K, Kokorovic A, Westerman M, Hensley P, Brooks N, Qiao W . Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy is Prognostic but Not Therapeutic. J Urol. 2022; 209(1):140-149. DOI: 10.1097/JU.0000000000003015. View

Chang S, Boorjian S, Chou R, Clark P, Daneshmand S, Konety B . Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 2016; 196(4):1021-9. DOI: 10.1016/j.juro.2016.06.049. View

Kamat A, Sylvester R, Bohle A, Palou J, Lamm D, Brausi M . Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. J Clin Oncol. 2016; 34(16):1935-44. PMC: 5321095. DOI: 10.1200/JCO.2015.64.4070. View

Gordon P, Thomas F, Noon A, Rosario D, Catto J . Long-term Outcomes from Re-resection for High-risk Non-muscle-invasive Bladder Cancer: A Potential to Rationalize Use. Eur Urol Focus. 2017; 5(4):650-657. DOI: 10.1016/j.euf.2017.10.004. View

Jin Y, Zeng X, Liu T, Bai Z, Dou Z, Ding D . Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition). Mil Med Res. 2022; 9(1):44. PMC: 9382792. DOI: 10.1186/s40779-022-00406-y. View

10.

Messing E, Tangen C, Lerner S, Sahasrabudhe D, Koppie T, Wood Jr D . Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA. 2018; 319(18):1880-1888. PMC: 6583489. DOI: 10.1001/jama.2018.4657. View

11.

Hashine K, Ide T, Nakashima T, Hosokawa T, Ninomiya I, Teramoto N . Results of second transurethral resection for high-grade T1 bladder cancer. Urol Ann. 2016; 8(1):10-5. PMC: 4719498. DOI: 10.4103/0974-7796.163798. View

12.

Jubber I, Ong S, Bukavina L, Black P, Comperat E, Kamat A . Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors. Eur Urol. 2023; 84(2):176-190. DOI: 10.1016/j.eururo.2023.03.029. View

13.

Flaig T, Spiess P, Abern M, Agarwal N, Bangs R, Boorjian S . NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022; 20(8):866-878. DOI: 10.6004/jnccn.2022.0041. View

14.

Bosschieter J, Nieuwenhuijzen J, van Ginkel T, Vis A, Witte B, Newling D . Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients. Eur Urol. 2017; 73(2):226-232. DOI: 10.1016/j.eururo.2017.06.038. View

15.

Teoh J, MacLennan S, Wai-Shun Chan V, Miki J, Lee H, Chiong E . An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting. Eur Urol. 2020; 78(4):546-569. DOI: 10.1016/j.eururo.2020.04.059. View

16.

Babjuk M, Burger M, Capoun O, Cohen D, Comperat E, Dominguez Escrig J . European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2021; 81(1):75-94. DOI: 10.1016/j.eururo.2021.08.010. View

17.

Cumberbatch M, Foerster B, Catto J, Kamat A, Kassouf W, Jubber I . Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. Eur Urol. 2018; 73(6):925-933. DOI: 10.1016/j.eururo.2018.02.014. View

18.

Eroglu A, Ekin R, Koc G, Divrik R . The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial. Int J Clin Oncol. 2019; 25(4):698-704. DOI: 10.1007/s10147-019-01581-0. View

19.

Han J, Gu X, Li Y, Wu Q . Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomed Pharmacother. 2020; 129:110393. DOI: 10.1016/j.biopha.2020.110393. View

20.

Sylvester R, Oosterlinck W, van der Meijden A . A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004; 171(6 Pt 1):2186-90, quiz 2435. DOI: 10.1097/01.ju.0000125486.92260.b2. View